does blue cross cover glp 1 drugs BCBSM pulling back on GLP-1 coverage The GLP-1 Access Gap: Mapping
Description
Lambert, J.-C
Most of the GLP-1RAs on the market are injection forms, and the development of oral dosage forms is very important to shape the potential of GLP-1RAs market in the future
29 GIP Agonism as a Potential Therapeutic Approach for Atherosclerotic Cardiovascular Disease The cardioprotective actions of incretin-based agents, particularly the GLP-1RAs, have a bulk of supporting evidence in the form of clinical studies
Setting Denmark, Norway, and Sweden, 2007-21
Makino H, Nakamura Y, Wada J
Afr Health Sci
